Dr. Karmali on Limitations of Intensive Therapy in Older/Medically Unfit Patients With MCL

Video

In Partnership With:

Reem Karmali, MD, MS, discusses the limitations of intensive therapy in older and medically unfit patients with mantle cell lymphoma (MCL).

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the limitations of intensive therapy in older and medically unfit patients with mantle cell lymphoma (MCL).

MCL is a rare and aggressive subtype of B-cell non-Hodgkin lymphoma, says Karmali. The majority of patients who are diagnosed with MCL are older. Additionally, these patients may have comorbidities or be medically unfit, thereby limiting their ability to undergo intensive chemoimmunotherapy with or without an autologous stem cell transplant (ASCT).

As such, these patients may have poorer outcomes, says Karmali. To that end, researchers conducted an analysis that evaluated the practice patterns and survival outcomes of patients 65 years of age or older with newly diagnosed MCL. The results were presented during the 2020 ASCO Virtual Scientific Program.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine